- Home
- ZNTL vs IRWD Comparison
ZNTL vs IRWD Comparison
Compare ZNTL & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZNTL
- IRWD
- Stock Information
- Founded
- ZNTL 2014
- IRWD 1998
- Country
- ZNTL United States
- IRWD United States
- Employees
- ZNTL N/A
- IRWD N/A
- Industry
- ZNTL Biotechnology: Pharmaceutical Preparations
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- ZNTL Health Care
- IRWD Health Care
- Exchange
- ZNTL Nasdaq
- IRWD Nasdaq
- Market Cap
- ZNTL 105.8M
- IRWD 97.4M
- IPO Year
- ZNTL 2020
- IRWD 2010
- Fundamental
- Price
- ZNTL $1.24
- IRWD $0.73
- Analyst Decision
- ZNTL Buy
- IRWD Buy
- Analyst Count
- ZNTL 7
- IRWD 5
- Target Price
- ZNTL $8.60
- IRWD $4.94
- AVG Volume (30 Days)
- ZNTL 1.4M
- IRWD 2.7M
- Earning Date
- ZNTL 08-08-2025
- IRWD 08-07-2025
- Dividend Yield
- ZNTL N/A
- IRWD N/A
- EPS Growth
- ZNTL N/A
- IRWD N/A
- EPS
- ZNTL N/A
- IRWD N/A
- Revenue
- ZNTL $26,865,000.00
- IRWD $317,676,000.00
- Revenue This Year
- ZNTL N/A
- IRWD N/A
- Revenue Next Year
- ZNTL N/A
- IRWD N/A
- P/E Ratio
- ZNTL N/A
- IRWD N/A
- Revenue Growth
- ZNTL N/A
- IRWD N/A
- 52 Week Low
- ZNTL $1.01
- IRWD $0.53
- 52 Week High
- ZNTL $5.44
- IRWD $7.11
- Technical
- Relative Strength Index (RSI)
- ZNTL 39.75
- IRWD 50.29
- Support Level
- ZNTL $1.31
- IRWD $0.66
- Resistance Level
- ZNTL $1.39
- IRWD $0.78
- Average True Range (ATR)
- ZNTL 0.11
- IRWD 0.07
- MACD
- ZNTL -0.03
- IRWD 0.01
- Stochastic Oscillator
- ZNTL 8.91
- IRWD 51.21
About ZNTL Zentalis Pharmaceuticals Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals Inc is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth plan for expanding its research, development, manufacturing, and marketing capabilities.